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Abstract
Peptic ulcers have unquestionably been a disease of the twentieth century. 
Epidemiological data for this disease and its complications have shown striking 
variation in incidence and prevalence. Various drugs have been used to treat peptic 
ulcer disease like proton-pump inhibitors, histamine (H2) receptor antagonists, 
prostaglandin analogues and sucralfate. Because these drugs are complex, expen-
sive and toxic, efforts have been constantly made to find a suitable, palliative and 
curative agent for the treatment of peptic ulcer disease from natural products of 
plant and animal origin. Recently, antioxidants are being used to treat peptic ulcer 
disease. Antioxidants help in scavenging the free radicals and controlling the oxida-
tive stress responsible for the progression of peptic ulcer.
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1. Introduction
Peptic ulcers have unquestionably been a disease of the twentieth century. 
Epidemiological data for this disease and its complications have shown striking 
variation in incidence and prevalence. Peptic ulcer is defined as a local defect or 
excavation on the surface of the stomach with a mucosal break of diameter 5 mm 
or larger, usually produced by sloughing of the inflammatory necrotic tissue. 
Aetiology of peptic ulcer is fiercely debated and is believed that peptic ulcers 
develop due to imbalance between aggressive factors (Helicobacter pylori, non-
steroidal anti-inflammatory drugs, gastric acid) and protective factors (mucin, 
bicarbonate, prostaglandins) leading to interruption of mucosal integrity [1].
The major forms of peptic ulcer include chronic duodenal ulcer, chronic gastric 
ulcer, Zollinger-Ellison syndrome (ZES), drug-induced ulcers and stress-induced 
peptic ulcer. Various factors are implicated to play a pivotal role in pathogenesis 
of ulceration like sedentary life style, alcohol, smoking, spicy food, physiological 
stress, drugs like non-steroidal anti-inflammatory drugs (NSAIDs) and various 
bacterial infections [1]. Oxidative stress has emerged as one of the major patho-
genic factors in progression of ulcer as it directly impairs the cellular function and 
promotes cellular organelle damage in mitochondria, lysosomes and nucleus [2].
Stress-induced peptic ulcer is a pathological condition affecting the gastrointes-
tinal tract. Stress ulcers are commonly found in the gastric mucosa anywhere within 
the stomach to the duodenum. Pathogenesis is mainly due to reduction in mucosal 
blood flow or a breakdown in other normal mucosal defence mechanisms. Effective 
therapy remains elusive in the treatment of stress-induced peptic ulcers [3]. One 
of the common denominators for the occurrence of the disease is involvement of 
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free radicals, an increase in histamine release and decreased mucous production. 
Reactive oxygen species are generated by various metabolic activities, and antioxi-
dant enzymes like superoxide dismutase, catalase, lipid peroxidase and glutathione 
peroxidase control their accumulation. Any imbalance in the activity of these 
enzymes leads to faulty disposal of free radical and their accumulation [4].
Alcohol is one of the leading causes of peptic ulcer disease. The mechanism of 
ethanol-induced gastric lesions is varied including the depletion of gastric mucus 
content, damaged mucosal blood flow and mucosal cell injury. It decreases 
bicarbonate and mucus production by which it produces necrotic lesion in gastric 
mucosa. Ethanol initiates apoptosis which leads to cell death. It also releases 
superoxide dismutase and hydroperoxyl free radical species in the biological 
system [4].
Various drugs have been used to treat peptic ulcer disease like proton-pump 
inhibitors, histamine (H2) receptor antagonists, prostaglandin analogues and 
sucralfate. Because these drugs are complex, expensive and toxic, efforts have been 
constantly made to find a suitable, palliative and curative agent for the treatment 
of peptic ulcer disease from natural products of plant and animal origin. Recently 
antioxidants are being used to treat peptic ulcer disease. Antioxidants help in 
scavenging the free radicals and controlling the oxidative stress responsible for the 
progression of peptic ulcer [2]. Coenzyme Q10 (CoQ10) and L-glutamine have 
antioxidant property, and their role as antioxidants has been documented in the 
literature in treating medical conditions [5–8].
2. Historical aspect
Gastric acid secretion had always been the topic of debate for the last 100 years 
with greater emphasis thrown on molecular as well cellular mechanisms involved 
in gastric acid secretion. Gastric juice was chemically analysed, and hydrochloric 
acid (HCL) was first isolated from gastric juice in 1824 by William Prout [9]. After 
the discovery of histamine (H2) receptor by James Black in 1971, antagonists were 
available for the treatment of peptic ulcer [10]. After the scintillating discovery of 
proton-pump inhibitors in 1989, the treatment of peptic ulcer was revolutionized as 
it blocks the final step of acid synthesis in the stomach lumen.
2.1 Gastric acid regulation
2.1.1 Central regulation
The central nervous system and enteric nervous system play a major role in the 
regulation of acid secretion along with hormones, paracrine agents as well as second 
messengers. The acid secretion occurs in three phases, namely, the cephalic, gastric, 
and intestinal phases [11]. The dorsal motor nucleus of the vagus (DMNV), the 
nucleus tractus solitarius (NTS) and the hypothalamus play a major role in central 
regulation of acid secretion. The DMNV plays a crucial role in integrating the 
sensory input from the hypothalamus and visceral input from the NTS and supplies 
efferent fibres to the stomach via the vagus, thereby primarily helping in motility 
rather than secretion. The ventromedial hypothalamus exerts an inhibitory influ-
ence on acid secretion with its stimulation causing decreased acid secretion and vice 
versa [11]. The sensory receptors of the stomach present within the muscle layer as 
well as mucosa of the stomach help in detecting the mechanical, chemical as well as 
the thermal stimuli, and these sensory impulses are carried to the central nervous 
system via sympathetic afferent as well as the vagal nerve fibres [11].
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2.1.2 Peripheral mechanism
Intrinsic mechanisms of the stomach regulate acid secretion, and these include 
neural stimulation via the vagus and gastrin and histamine release from G cells 
and enterochromaffin-like (ECL) cells, respectively. All these stimuli directly act 
on the parietal cells. Acetylcholine also helps in the regulation of acid secretion 
[12]. The histamine released acts on the histamine receptor type 2 (H2) on the 
parietal cells, leading to activation of cyclic adenosine monophosphate pathway 
and calcium-sensitive pathway resulting in stimulation of H+ K+-ATPase on 
parietal cells [13].
2.2 Mechanisms of cytoprotection
The term cytoprotection coined by Robert is defined as protection against gas-
tric mucosal injury by mechanisms other than neutralisation of gastric acid [14]. An 
explosion of investigations led to the discovery that endogenous prostaglandins are 
involved in cytoprotection via putative mechanisms which includes mucus secre-
tion, release of bicarbonate, maintenance and strengthening of mucosal blood flow 
and free radical scavenging [15–18]. The normal gastric mucosa without exogenous 
insult remains hostile to the acidic milieu of gastric lumen. Gastric mucosal defence 
can be categorised into pre-epithelial defence which is secretion of mucus gel, 
epithelial defence with surface epithelial cells withstanding pH <2.5 and the post-
epithelial barrier with parietal cells at the base of the gland [19].
2.2.1 Stimulation of mucus and bicarbonate secretion
The mucus barrier is made of mucus, lipids and proteins. These form a continu-
ous gel and along with bicarbonate secretion protect the stomach from acidic insult 
[20]. Cytoprotective agents like prostaglandins have shown to increase the mucus 
gel thickness but does not protect the surface epithelium in contrast to protection of 
the deeper layers [21]. Mucin also helps in reepithelization of mucosa. It was identi-
fied that bicarbonate helps in cytoprotection and acts by metabolically dependent 
process as well as by passive diffusion [22]. Prostaglandins help in increasing the 
bicarbonate secretion, and bicarbonate in turn forms the mucus bicarbonate barrier 
[23]. Bicarbonate also directly helps in lowering the hydrogen ion concentration in 
the gastric mucosa [14].
2.2.2 Strengthening of gastric mucosal barrier
The apical membrane, the so-called tight junctions between the surface 
epithelial cells, prevents back diffusion of acid and hence forms a major muco-
sal barrier. Phospholipids on the luminal surface of gastric epithelium form 
a hydrophobic lining and thereby contribute in preventing the water-soluble 
hydrogen ions to pass through. Prostaglandins increase concentration of these 
phospholipids [24].
2.2.3 Regulation of mucosal blood flow
Vascular injuries to sub-epithelial capillaries with increased vascular permeabil-
ity and circulatory stasis lead to functional impairment of gastric microcirculation. 
Upregulation of mucosal blood flow maintains oxygenation and nutrient supply. 
Increase in blood supply to mucosa helps in regulating bicarbonate mediated acid 
neutralisation and in absorption of injurious agents [25].
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2.2.4 Effects on gastric motility
Mucosal compression is said to play an important role in epithelial necrosis and 
ulceration. Gastric hypercontraction accounts for mucosal compression. The gastric 
mucosa is protected by the action of circular muscles which causes flattening of gastric 
mucosal folds, thereby leading to increase in mucosal surface area ultimately reducing 
volume of irritants coming in contact with the mucosa. Various substances like prosta-
glandins and mast cell stabilisers aid in this process adding to cytoprotection [26].
2.2.5 Scavenging free radicals
Free radicals cause lipid peroxidation and damage to intracellular components. It 
leads to ischemia of gastric mucosa, thereby causing severe damage to the mucosa. 
Vitamin E and selenium are well-known antioxidants shown to have protective 
effect on stress and chemical-induced gastric lesions [27].
2.2.6 Endogenous mediators on gastric cytoprotection
Prostaglandins, L-cysteine, methionine and epidermal growth factor are said 
to be cytoprotective. Imbalance between two metabolites of arachidonic pathway 
is also said to contribute to gastric injury. Literature data suggests prostaglandins 
help in gastric protection by increasing the gastric blood supply and decreasing 
the synthesis of leukotrienes, thus playing a significant role in cytoprotection [28]. 
Therefore, cytoprotection is a multifactorial phenomenon.
2.3 Pathogenesis of peptic ulcer
Peptic ulcers are chronic with ~99% ulcers occurring in the duodenum and 
stomach with the former being four times higher than the latter [29]. Factors caus-
ing peptic ulcers include increased acid secretion, impaired mucosal defence, free 
radical and lipid peroxidation.
2.3.1 Increased acid secretion
Pepsin activity in gastric juice and acidity of gastric juice are important deter-
minants of ulcer formation. The famous Schwartz’s dictum “no acid-no ulcer” 
becomes accurate when amplified to “no acid and peptic activity”, as pepsin con-
tributes to the digestive power of the stomach. This dictum is supported by various 
therapeutic drugs like antacids and anti-secretory drugs, but much to everyone’s 
anguish, ulcer recurs once therapy is stopped [30].
2.3.2 Impaired mucosal defence
The tight epithelial junctions form a barrier preventing hydrogen ion back diffu-
sion. Recent evidences suggest surface phospholipids form a hydrophobic lining on 
the gastric epithelium and hence retard the passage of hydrogen ions. NSAIDS and 
Helicobacter pylori infection disrupt the mucosal barrier and are known to increase 
the diffusion of hydrogen ions [31].
2.3.3 Free radical and peroxidation
Free radical contains unpaired electrons, and it plays an important role in patho-
genesis of ischemia/reperfusion injury. Free radicals can nick deoxyribonucleic acid 
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(DNA) and provoke uncontrolled chain reactions like lipid peroxidation. Acute and 
chronic gastric ulcers are caused by oxygen-derived free radicals, and in one study, 
infusion of superoxide-generating system into rat celiac artery-induced gastrointes-
tinal bleeding was shown [32].
2.4 Predisposing factors for peptic ulceration
2.4.1 Helicobacter infection
Helicobacter pylori causes antral gastritis in more than 95% of patients with 
duodenal ulcer than 75% with gastric ulcer. This organism adheres to the mucosal 
epithelium close to the gap junctions and releases urea and ammonia producing an 
alkaline environment with raised pH. This creates an environment for the organ-
ism to survive, and release of ammonia is cytotoxic to the gastric cells. Gastric 
metaplasia occurs, and colonisation of these heterotrophic islands results in 
mucosal injury and gastric ulceration. Oxidative stress has been implicated in the 
pathogenesis of Helicobacter pylori infections, and increased oxidative damage by 
Helicobacter pylori is responsible for epithelial injury, altered epithelial prolifera-
tion and increased apoptosis [33].
2.4.2 Non-steroidal anti-inflammatory drugs
NSAIDs are known to cause various injuries in the gastric tract ranging from 
haemorrhages and petechiae to erosions with ulcers. These drugs are known to 
cause mucus glycoprotein denaturation in the stomach and sloughing of epithelial 
cells. Also, drugs like aspirin causes intracellular protons to accumulate in the 
parietal cells and leads to localised acid accumulation by the process called back 
diffusion of acid. These drugs also cause labialization of lysosomes leading to cel-
lular autolytic reactions, inhibition of prostaglandins and mast cell degranulation 
leading to histamine release, inhibition of glucose oxidation and enzymes involved 
in anabolic reactions. It also increases the production of free radicals [34].
2.4.3 Cigarette smoking
Healing of ulcers is affected by smoking, and it is a known fact that gastric 
ulcers occur more frequently in smokers. Various theories are put forward as to 
why cigarette smoking causes ulcers, and some of them includes stimulation of 
acid secretion, blood flow alteration to gastric mucosa, induction of bile reflux and 
reduced prostaglandin synthesis [35].
2.4.4 Psychological stress
The CNS and brain gut axis play an important role in stress ulcerogenesis. 
Various conditions like shock, sepsis, trauma and neurological disorders are now 
regarded as multifactorial phenomenon. Various interactions between vascular, 
mucosal and neurohumoral factors and the autonomic nervous system play a criti-
cal role in stress ulcerogenesis. Limbic area plays a pertinent role in modulating acid 
secretion, motility and blood flow [36].
2.4.5 Alcohol
Ethanol causes cell and plasma membrane damage leading to increased mem-
brane permeability finally causing accumulation of sodium and water. It also causes 
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free radical release leading to lipid peroxidation causing gastric lesions. Patients with 
cirrhosis due to alcohol also have increased incidence of peptic ulcer [37] (Figure 1).
2.5 Therapy for acute peptic ulcer
Gastric acid secretion and mucosal defence mechanism have been the target to 
treat peptic ulcer disease. This has led to discovery of many drugs to treat peptic 
ulcer disease, and few treatment options have stood the test of time as shown  
in Table 1 [38].
2.5.1 H+/K+ ATPase inhibitors
It acts by directly blocking the gastric proton pump rather than blocking 
histamine and cholinergic receptors. There are many drugs available in this class, 
namely, omeprazole, lansoprazole, rabeprazole and pantoprazole. They block the 
final step in the acid secretion and thereby have better control over basal as well as 
nocturnal acid secretion. They are also known to inhibit the growth of Helicobacter 
pylori [38]. They are now used as first-line agents in the treatment of peptic ulcer, 
and it has replaced H2 antagonists.
2.5.2 Prostaglandins
Robert in 1979 showed prostaglandins inhibit gastric acid secretion and help 
in protection against ulcers caused by NSAIDs, diet, alcohol, smoking and stress. 
Misoprostol, a prostaglandin analogue, acts by increasing the secretion of mucus 
as well as bicarbonate, thereby protecting against chronic ulcers. But it helps only 
in protection against gastric ulcer and not against duodenal ulcers [39]. It is contra-
indicated in pregnancy due to its abortifacient property. Enprostil, rioprostil and 
arbaprostil are other known compounds. Other drugs in clinical trials are noclo-
prost, enisoprost and mexiprost [39].
Figure 1. 
Pathogenesis of peptic ulcer.
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2.5.3 H2 receptor antagonists
These drugs act by blocking the H2 receptor and thereby reduce the release of 
gastric acid. It is very helpful in reducing 90% of the basal, food-stimulated and 
nocturnal secretion of gastric acid as well. Literature evidence says it also helps 
in prevention of stress-induced gastric ulcers. They are used in combination with 
antacids in the treatment of stress-induced ulcers. These drugs include mainly 
ranitidine, cimetidine, famotidine and nizatidine. One of the major drawbacks is 
long duration of administration for ulcer therapy, and recurrence of ulcer after 
healing is a frequent complication [40].
2.5.4 Muscarinic receptor antagonists
Pirenzepine has more cytoprotective effects when compared with histamine 
receptor antagonists. It helps in protection against gastric mucosal lesions induced 
by alcohol, sodium hydroxide (NAOH) and taurocholate. It exerts its action via 
inhibition of muscarinic (M1) receptor present in the stomach and reduces basal as 
well as stimulated acid secretion [41].
2.5.5 Mucosal coating agents
Sucralfate is a basic sulphated disaccharide with aluminium sulphate complex. 
It helps in forming an adherent coating at the mucosal sites which are ulcerated. It 
acts by reducing pepsin activity, adsorbs bile salts and acts as barrier to hydrogen 
ion diffusion. It also binds to both epidermal growth factor (EGF) and fibroblast 
growth factor (FGF) and helps in enhancing ulcer healing. It is found effective in 
Helicobacter pylori infection [42].
3. Coenzyme Q10
Morton in 1955 in Liverpool identified a quinone-like substance with an ultraviolet 
absorption at 272 nm from intestinal mucosa of horses and named it as ubiquinone. 
Class of drugs Mechanisms Use
H2 receptor antagonists 
(cimetidine, ranitidine, 
famotidine, nizatidine, roxatidine)
Acid inhibition H. pylori-negative peptic ulcer; replaced 
by PPI because of inferiority in acid 
suppression
PPI (omeprazole, pantoprazole, 
lansoprazole, rabeprazole, 
esomeprazole)
Most potent acid inhibition Standard treatment for all H. pylori-
negative peptic ulcers; prevention 
of NSAID or aspirin ulcers; essential 
component in eradication regimen; 
given intravenously in bleeding ulcers
Prostaglandin analogues 
(misoprostol*)
Increase mucosal resistance; 
weak acid inhibition
H. pylori-negative gastric ulcer; 
prevention of NSAID ulcers
H. pylori eradication regimens 
(PPI plus two antibiotics)
Cure of H. pylori infection Standard therapy in all H. pylori-positive 
ulcers
Bismuth salts (subcitrate, 
subsalicylate)
Weak antibacterial effect; 
increase of mucosal 
prostaglandin synthesis
In quadruple therapy for H. pylori 
eradication
PPI = proton-pump inhibitor, NSAID = non-steroidal anti-inflammatory drug*Contraindicated in pregnancy
Table 1. 
Class of drugs with effect on healing of peptic ulcer.
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Crane and his colleagues in the University of Wisconsin isolated quinone in lipid 
extracts of mitochondria and named it coenzyme Q because of its unique role in cel-
lular metabolism and energy production. Ernster, a Swedish scientist, expanded the 
benefits of this molecule as an antioxidant and free radical scavenger. Coenzyme Q10 
also plays a major proton-motive role in the energy transfer systems [43].
Coenzyme Q10 is an active quinone with a benzoquinone ring along with 10 isopren-
oid side chains. It is structurally related to vitamin K and vitamin E. Naturally it is orange 
in colour without odour and taste with a molecular weight of 863.34 g/mol. It is stable at 
temperatures below 46°C. CoQ10 is the prevalent form in humans in contrast to CoQ9 in 
rats and Q6, Q7 and Q8 in yeast and bacteria. It exists in three forms, the fully oxidised 
ubiquinone; semiquinone, the free radical form; and ubiquinol, the reduced form [44].
CoQ10 is found in every cell of the human body, mainly located in the phospho-
lipid bilayer of various membranes. It is found in higher concentrations in the heart, 
liver, muscles and pancreas, which have high energy requirements. It is derived 
from tyrosine with several vitamins and trace elements as cofactors. Because of this 
complex biosynthesis, human enzyme and protein defects may cause deficiency 
of CoQ10 in infants as well as adults. Cellular functions depend on production of 
adenosine triphosphate (ATP) in mitochondria making electron and proton transfer 
functions of quinone ring very important in all life forms [43].
Coenzyme Q10 is usually absorbed from the small intestine, and bioavailability 
depends on the type of preparation and on the route of administration. Evidence 
says it is absorbed orally with almost 178% increase in serum levels. Some studies 
also say it is absorbed very minimally due to its lipophilic nature and huge molecu-
lar weight. Oil-based preparations of CoQ10 have better absorption [44].
It plays a vital role as intermediate in mitochondrial electron transport chain. 
CoQ10, an endogenously synthesised lipid-soluble antioxidant along with alpha-
tocopherol, acts in scavenging the free radicals generated in the inner mitochondrial 
membrane. CoQ10 also prevents lipid peroxidation in cells depleted of alpha-tocoph-
erol. It helps in protection of DNA from free radical injury, in recycling of antioxidants 
such as tocopherol and ascorbate with additional role in cell signalling and gene expres-
sion. A direct evidence for the antioxidant property of CoQ10 is shown in literature, 
where luminescence is eliminated from free radicals when skin cream containing 
coenzyme Q10 is applied demonstrating the elimination of free radicals by CoQ10. It 
also helps in maintaining cellular respiration and ATP synthesis. It also helps in decreas-
ing calcium overload in tissues by indirectly stabilising calcium channels [45].
CoQ10 deficiencies are due to autosomal recessive mutations, mitochondrial 
diseases, ageing-related oxidative stress, carcinogenesis processes and also treatment 
with statins. Many neurodegenerative disorders, diabetes, cancer and muscular and 
cardiovascular diseases have been associated with low CoQ10 levels as well as differ-
ent ataxias and encephalomyopathies [45, 46]. CoQ10 is generally very well tolerated 
at doses not exceeding 500 mg. Gastrointestinal (digestive) distress is reported with 
doses up to 3000 mg daily [45]. Recent evidence also says coenzyme Q10 is used in 
treatment of peptic ulcer. Few animal studies have tried the use of coenzyme Q10; in 
one study, indomethacin-induced ulcer in Wistar rats was treated using coenzyme 
Q10, and favourable results were obtained [47]. CoQ10-mediated gastroprotective 
effect involves preservation of microvascular permeability, elevation of prostaglan-
din E₂, improvement of redox status as well as boosting of nitric oxide.
4. Glutamine
Glutamine is one of the 20 amino acids encoded by standard genetic code. It is 
considered a conditionally essential amino acid. Its side chain is an amide formed by 
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replacing hydroxyl side chain of glutamic acid. In humans, blood glutamine is the 
most abundant free amino acid, with concentration of about 500–900 μmol/L. It 
is mainly helpful in protein synthesis, acid base balance, cellular energy (next to 
glucose), nitrogen donation for anabolic process, carbon donation in citric acid 
cycle and ammonia transporter in blood circulation. It is produced by enzyme glu-
tamine synthetase from glutamate/ammonia in muscles. Almost 90% of glutamine 
is synthesized in the muscles [48]. Consumers are cells of the intestine, kidney cells 
and immune/cancer cells. It is used in cachexia, to reduce infections and to control 
gut leak after surgery. It also increased intestinal barrier and intestinal perme-
ability. As a preferred substrate for enterocytes, glutamine has shown to support 
the normal immunological structure and function of the gastrointestinal tract. In 
animal studies glutamine deprivation is associated with loss of intestinal epithelial 
integrity, while glutamine supplementation decreases gastrointestinal tract mucosal 
atrophy. Glutamine also restored ATP levels and reduces cell apoptosis. It is very 
important during stress and catabolic conditions [49]. So far only one animal study 
has evaluated the use of L-glutamine in aspirin-induced peptic ulcer model. They 
found out the L-glutamine was effective in protecting against aspirin-induced 
gastric lesions in rats [50]. L-Glutamine, commonly used in sports medicine for 
muscle recovery, has gained medical importance because of its antioxidant proper-
ties [51]. The antioxidant properties of L-glutamine has been claimed to be useful in 
the treatment of peptic ulcer disease in animal studies as well as in very few human 
studies. Only a few animal studies have been done so far to investigate the role of 
L-glutamine in the treatment of Helicobacter pylori infections, and it was found to 
be positive, yet human trials have not been done in large [52, 53].
4.1 Ulcer induction methods
Clinical ulcers are usually chronic and are penetrating lesions in comparison with 
experimentally induced lesions which are acute non-penetrating ulcers healing at 
faster rates without scar formation. Even though experimental lesions have some 
limitation, it is still possible to evaluate the therapeutic agents rapidly with reasonable 
predictability for their therapeutic use. There are various animal models used for 
evaluating gastric ulcers, and some of the most important will be described below.
Criteria for experimental ulcers proposed by Lee and Bianchi are as follows [54]:
1. It should be simple and easily reproducible with easy quantification of results.
2. Variety of animal species should be made use of.
3. Ulcer should be produced in characteristic sites like the stomach and the first 
part of the duodenum.
4. Models should include different mechanisms by which ulcers are produced.
5. There should not be any spontaneous healing of ulcers during the observation 
period.
The various methods available are discussed in the next subsections.
4.1.1 Pylorus ligated rat
Ulcers produced by this method are also called as Shay ulcers as it was first dem-
onstrated by Shay in 1945. In this model, the animals are usually housed in individual 
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cages and fasted for 36 h before ligating the pylorus. The abdomen is opened after 
anesthetising the rats by a small midline incision just below the xiphoid process. 
Then the pyloric part of the stomach is ligated without compromising its vascularity. 
Later the abdomen is closed in layers using interrupted sutures. The animal is made 
to starve completely without water and is sacrificed after 19 h. The stomach is then 
dissected out, and the contents of the stomach are used to determine the pH, volume 
of gastric juice and free and total acidity. The stomach is then cut open along the 
greater curvature and examined for ulceration. Circular lesions and linear lesions 
are observed. This model usually has a greater predictive value for antiulcer agents 
though ulcers in this model are usually localised in the ruminal area of the stomach 
in comparison to human ulcers which are usually located in the glandular portion of 
the stomach and duodenal region [55].
4.1.2 Stress ulcers
These ulcers are usually produced by subjecting any species to different types of 
stress. This model is very easy as it is devoid of any experimental surgery and usage 
of anaesthesia. It mainly involves the central nervous system, and produced lesions 
are located in the glandular portion of the stomach.
5. Restraint ulcers
This method was first used by Brodie and Hansen in 1960. Rats are usually 
fasted for 36 h before the experiment. Later each rat is placed in a piece of galvan-
ised steel window screen of appropriate size. The screen is then moulded around 
each rat and is held together with wire staples. The animals are made immobile by 
tightening the limbs together. The test drug is administered 30 min before subject-
ing the animals to restraint. After 24 h the animals are sacrificed, and their stomach 
is dissected out along the greater curvature and is subjected to assessment. One 
drawback of this method was the ulcers were not deep as they did not penetrate 
the muscularis mucosa and penetrating ulcers were not produced. Some com-
monly used modifications of this method to overcome the drawbacks include water 
immersion-induced restraint ulcer, cold and restraint ulcer, swimming stress ulcers 
and also stress with concurrent administration of NSAIDs and also haemorrhagic 
shock-induced gastric ulcers in rats [56].
5.1 NSAID-induced gastric mucosal damage
The routinely used drug for experimental induction of ulcers includes diclof-
enac, ibuprofen, indomethacin, phenylbutazone and aspirin. Usually the test 
agents are administered 30 min–1 h before the noxious challenge. Later after 4 h the 
animals are sacrificed and examined for mucosal lesions in the stomach [57].
5.1.1 Histamine-induced gastric ulcers
The vasospastic and the gastric secretion increases shown via the histamine 
receptors attribute to ulcer formation in this model. It was first described in 1947 in 
guinea pigs. It was noted that in this model 100% ulceration was produced with 
notable increase in volume of gastric secretion as well as increment in free and 
total acidity. Usually the animals are fasted for 36 h, and ulcers are induced by 
injecting 1 ml of histamine acid phosphate (50 mg base) via intraperitoneal route. 
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5 mg intraperitoneally 15 min prior to and 15 min after histamine administration, 
respectively. The investigational drug is usually administered 45 min before inject-
ing histamine. After 4 h the animals are sacrificed; and assessment of the stomach is 
done after dissection, and various indices are calculated [58].
5.1.2 Acetic acid-induced chronic gastric ulcers
Acetic acid at a concentration of 1–30% is used, and usually 0.05 ml per rat is 
used. It is injected to the submucosal layer of the stomach, penetrating ulcers usu-
ally produced can be noted with gross examination, and ulcers are mostly confined 
by adhesion to contiguous organs. It can be successfully used to screen new antiul-
cer agents [59].
5.1.3 Serotonin-induced gastric ulcers
Wilhelmi, Wedinger and Veraguth described this method in Wistar rats. Usually 
rats are fasted for 24 h, and later serotonin creatinine sulphate is dissolved in saline 
and injected subcutaneously into rats. Usually serotonin is used at a dose of 20 mg/
kg, and with this dose, moderate gastric lesions are noted [60].
5.1.4 Ethanol-induced gastric ulcers.
Eighty percent of ethanol in a dose of 5 ml/kg of body weight is usually given 
orally to the albino rats. If administered intraperitoneally, 40% of ethanol is given, 
and usually animals are observed for a period of 7–14 days [61].
6. Conclusion
Peptic ulcer being a global problem proper treatment is warranted. Proper 
screening of Helicobacter pylori and ruling out other possible causes could benefit 
the patient in getting cured with the correct treatment. The latest research proves 
oxidative stress as one of the major contributing factors for peptic ulcer disease, 
so the use of antioxidants as a potential agent is highly warranted. Further clinical 
trials can be done to elicit the efficacy of these antioxidants as potential anti-peptic 
ulcer drugs.
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